Phaseline

Companies › VeonGen Therapeutics

VeonGen Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Ophthalmology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VG801
Gene therapy for ABCA4 mutation-associated retinal dystrophy
ABCA4Phase 1Retinal Dystrophy Due to Biallelic ABCA4 MutationsDec 2027
VG901
AAV2-mediated gene therapy delivering functional CNGA1 gene
CNGA1Phase 1Retinitis Pigmentosa–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06291935VG901Phase 1Retinitis PigmentosaOphthalmologyApr 2026
NCT07002398VG801Phase 1Retinal Dystrophy Due to Biallelic ABCA4 MutationsOphthalmologyDec 2027

Targets

CNGA1 (1) ABCA4 (1)

Companies with the same targets

Ascidian Therapeutics AAVantgarde Bio Srl

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.